MetaVia (MTVA) Competitors $1.60 -0.16 (-9.09%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends MTVA vs. GBIO, CLSD, IMAB, OVID, FBLG, THTX, AVTE, PDSB, HOWL, and EPIXShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Generation Bio (GBIO), Clearside Biomedical (CLSD), I-Mab (IMAB), Ovid Therapeutics (OVID), FibroBiologics (FBLG), Theratechnologies (THTX), Aerovate Therapeutics (AVTE), PDS Biotechnology (PDSB), Werewolf Therapeutics (HOWL), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical preparations" industry. MetaVia vs. Generation Bio Clearside Biomedical I-Mab Ovid Therapeutics FibroBiologics Theratechnologies Aerovate Therapeutics PDS Biotechnology Werewolf Therapeutics ESSA Pharma MetaVia (NASDAQ:MTVA) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends. Does the media refer more to MTVA or GBIO? In the previous week, MetaVia had 3 more articles in the media than Generation Bio. MarketBeat recorded 3 mentions for MetaVia and 0 mentions for Generation Bio. MetaVia's average media sentiment score of 0.08 beat Generation Bio's score of 0.00 indicating that MetaVia is being referred to more favorably in the media. Company Overall Sentiment MetaVia Neutral Generation Bio Neutral Is MTVA or GBIO more profitable? MetaVia has a net margin of 0.00% compared to Generation Bio's net margin of -782.86%. Generation Bio's return on equity of -104.85% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -189.12% -122.31% Generation Bio -782.86%-104.85%-49.54% Which has more volatility and risk, MTVA or GBIO? MetaVia has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.66, meaning that its share price is 166% more volatile than the S&P 500. Do analysts rate MTVA or GBIO? Generation Bio has a consensus price target of $7.50, suggesting a potential upside of 530.25%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Generation Bio is more favorable than MetaVia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Generation Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in MTVA or GBIO? Generation Bio received 42 more outperform votes than MetaVia when rated by MarketBeat users. CompanyUnderperformOutperformMetaViaN/AN/AGeneration BioOutperform Votes4270.00% Underperform Votes1830.00% Do insiders & institutionals have more ownership in MTVA or GBIO? 1.4% of MetaVia shares are held by institutional investors. Comparatively, 95.2% of Generation Bio shares are held by institutional investors. 1.1% of MetaVia shares are held by company insiders. Comparatively, 21.1% of Generation Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, MTVA or GBIO? MetaVia has higher earnings, but lower revenue than Generation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$12.47MN/AN/AGeneration Bio$18.58M4.28-$126.61M-$2.19-0.54 SummaryGeneration Bio beats MetaVia on 10 of the 14 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.79M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E RatioN/A10.5991.3417.19Price / SalesN/A195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book0.475.104.794.78Net Income-$12.47M$151.51M$120.07M$225.60M7 Day Performance-26.94%-2.14%-1.90%-1.24%1 Month PerformanceN/A-3.13%11.43%3.06%1 Year PerformanceN/A11.51%30.59%16.50% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaViaN/A$1.60-9.1%N/AN/A$13.79MN/A0.00N/ANews CoverageGap DownGBIOGeneration Bio2.7569 of 5 stars$1.09-6.0%$7.50+588.1%-30.0%$77.48M$18.58M-0.50150Positive NewsCLSDClearside Biomedical2.8912 of 5 stars$1.02+1.0%$5.33+422.9%-12.8%$77.36M$7.70M-2.2430News CoverageIMABI-Mab2.5162 of 5 stars$0.95-1.0%$8.00+746.3%-38.9%$77.04M$3.27M0.0034Gap DownOVIDOvid Therapeutics4.3822 of 5 stars$1.06+1.0%$4.04+281.1%-71.8%$75.27M$631,695.00-2.2660Positive NewsFBLGFibroBiologics1.8409 of 5 stars$2.15-0.5%$13.00+504.7%N/A$74.52MN/A0.0010Positive NewsTHTXTheratechnologiesN/A$1.62-1.2%N/A+16.2%$74.49M$84.32M-16.20140High Trading VolumeAVTEAerovate Therapeutics1.252 of 5 stars$2.56flat$2.25-12.1%-86.4%$73.92MN/A-0.8651Short Interest ↓Positive NewsPDSBPDS Biotechnology1.1426 of 5 stars$1.96+1.0%$11.67+495.2%-66.0%$73.32MN/A-1.6920Analyst ForecastNews CoverageHOWLWerewolf Therapeutics3.7637 of 5 stars$1.64-1.2%$12.00+631.7%-44.8%$73.08M$3.39M-1.0740Positive NewsEPIXESSA Pharma3.3486 of 5 stars$1.64+0.6%$9.50+479.3%-73.8%$72.77MN/A-2.6350Earnings ReportPositive NewsGap Up Related Companies and Tools Related Companies GBIO Alternatives CLSD Alternatives IMAB Alternatives OVID Alternatives FBLG Alternatives THTX Alternatives AVTE Alternatives PDSB Alternatives HOWL Alternatives EPIX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MTVA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
